Eli Lilly enters into strategic partnership on metabolic diseases with Regor Therapeutics

US-based Eli Lilly and Regor Therapeutics Group have entered into a development collaboration and licensing agreement to discover, develop and commercialize new therapies within metabolic diseases like diabetes and obesity.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app